Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 2 (2005), Issue 3 (March)

1. Clinical course and prognosis of 27 patients with childhood onset multiple sclerosis in Japan.
   Brain Dev, 27(3): 224-7. [Abstract] [Full-text]
2. Intestinal pseudo-obstruction complicating multiple sclerosis.
   Intern Med J, 35(3): 191-2. [Abstract] [Full-text]
3. Further considerations on the distribution of multiple sclerosis in Sweden.
   Acta Neurol Scand, 111(4): 238-46. [Abstract] [Full-text]
4. IFNG polymorphisms are associated with gender differences in susceptibility to multiple sclerosis.
   Genes Immun, 6(2): 153-61. [Abstract] [Full-text]
5. Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis.
   Genes Immun, 6(2): 145-52. [Abstract] [Full-text]
6. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis.
   Nat Med, 11(3): 328-34. [Abstract] [Full-text]
7. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis.
   Nat Med, 11(3): 335-9. [Abstract] [Full-text]
8. Platelet-activating factor receptor gene polymorphism in Japanese patients with multiple sclerosis.
   J Neuroimmunol, 161(1): 195-8. [Abstract] [Full-text]
9. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology.
   J Neuroimmunol, 161(1): 190-4. [Abstract] [Full-text]
10. Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis.
    J Neuroimmunol, 161(1): 169-76. [Abstract] [Full-text]
11. Determination of the sequential degradation of myelin proteins by macrophages.
    J Neuroimmunol, 161(1): 12-20. [Abstract] [Full-text]
12. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis.
    J Neurochem, 92(6): 1327-39. [Abstract] [Full-text]
13. Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis.
    J Biol Chem, 280(10): 8985-93. [Abstract] [Full-text]
14. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments.
    Breast Cancer Res Treat, 89(3): 265-70. [Abstract] [Full-text]
15. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients.
    J Exp Med, 201(5): 805-16. [Abstract] [Full-text]
16. Dopamine exerts no acute effects on Kv1.3 in activated encephalitogenic T cells.
    Neuroimmunomodulation, 12(1): 45-53. [Abstract] [Full-text]
17. Immunological study of IFNbeta-1a-treated and untreated multiple sclerosis patients: clarifying IFNbeta mechanisms and establishing specific dendritic cell immunotherapy.
    Neuroimmunomodulation, 12(1): 29-44. [Abstract] [Full-text]
18. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis.
    Neurobiol Dis, 18(3): 537-50. [Abstract] [Full-text]
19. Benefit finding in multiple sclerosis and associations with positive and negative outcomes.
    Health Psychol, 24(2): 123-32. [Abstract] [Full-text]
20. The nature of care giving in a community sample of people with multiple sclerosis.
    Disabil Rehabil, 26(24): 1401-10. [Abstract] [Full-text]
21. Indication for psychotherapy in offspring of a parent affected by a chronic somatic disease (e.g. multiple sclerosis).
    Psychopathology, 38(1): 38-48. [Abstract] [Full-text]
22. Depression in multiple sclerosis: a quantitative review of the evidence.
    Neuropsychology, 19(2): 152-8. [Abstract] [Full-text]
23. Immunology of multiple sclerosis.
    Annu Rev Immunol, 23: 683-747. [Abstract] [Full-text]
24. Predictive value of the CES-D in detecting depression among candidates for disease-modifying multiple sclerosis treatment.
    Psychosomatics, 46(2): 131-4. [Abstract] [Full-text]
25. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry, 76(4): 519-26. [Abstract] [Full-text]
26. Depression in multiple sclerosis: a review.
    J Neurol Neurosurg Psychiatry, 76(4): 469-75. [Abstract] [Full-text]
27. Sensory function and quality of life in patients with multiple sclerosis and pain.
    Pain, 114(3): 473-81. [Abstract] [Full-text]
28. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?
    Rheumatology (Oxford), 44(4): 434-42. [Abstract] [Full-text]
29. Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis?
    Br J Dermatol, 152(3): 537-40. [Abstract] [Full-text]
30. Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity.
    Invest Ophthalmol Vis Sci, 46(4): 1264-8. [Abstract] [Full-text]
31. Multiple sclerosis.
    Immunol Rev, 204: 208-31. [Abstract] [Full-text]
32. Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses.
    J Neurol Sci, 231(1): 41-4. [Abstract] [Full-text]
33. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change.
    J Neurol Sci, 231(1): 29-34. [Abstract] [Full-text]
34. Cyclopentenone prostaglandins PGA2 and 15-deoxy-delta12,14 PGJ2 suppress activation of murine microglia and astrocytes: implications for multiple sclerosis.
    J Neurosci Res, 80(1): 66-74. [Abstract] [Full-text]
35. Sleep disorders in multiple sclerosis.
    Semin Neurol, 25(1): 64-8. [Abstract] [Full-text]

© 2004-2008 Multiple Sclerosis Research Today. All Rights Reserved.